L3VLUP
ProSign in

ASND · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ASNDVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ASND
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterASNDVRTX
Q3 20209 holders, $4.1bn31 holders, $21.9bn
Q4 202012 holders, $4.5bn30 holders, $18.4bn
Q1 202110 holders, $3.4bn31 holders, $15.4bn
Q2 202110 holders, $3.4bn30 holders, $12.7bn
Q3 202110 holders, $4.5bn35 holders, $10.1bn
Q4 202111 holders, $3.7bn28 holders, $12.4bn
Q1 202210 holders, $3.3bn23 holders, $16.1bn
Q2 20229 holders, $2.5bn25 holders, $18.1bn
Q3 202212 holders, $2.7bn22 holders, $18.4bn
Q4 202212 holders, $3.0bn28 holders, $18.4bn
Q1 20239 holders, $2.6bn26 holders, $21.4bn
Q2 20238 holders, $1.9bn27 holders, $24.7bn
Q3 20238 holders, $2.0bn33 holders, $24.3bn
Q4 202311 holders, $2.8bn32 holders, $28.6bn
Q1 202416 holders, $3.4bn31 holders, $29.8bn
Q2 202414 holders, $2.8bn29 holders, $33.4bn
Q3 202415 holders, $3.1bn27 holders, $33.5bn
Q4 202411 holders, $2.6bn26 holders, $28.5bn
Q1 202513 holders, $3.2bn21 holders, $35.4bn
Q2 202511 holders, $3.2bn21 holders, $32.3bn
Q3 202515 holders, $3.7bn22 holders, $25.9bn
Q4 202514 holders, $3.7bn26 holders, $31.8bn
Q1 202610 holders, $3.1bn25 holders, $31.8bn
Q2 202612 holders, $4.3bn26 holders, $34.6bn
ASND

Ascendis Pharma A

Holders
16
Reported value
$3.4bn
Buyers
10
Sellers
6

Breadth +4 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ASND (4)

Baillie Gifford & Co, Farallon Capital Management LLC, Soros Fund Management LLC, Woodline Partners LP

Only VRTX (19)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, ExodusPoint Capital Management LP, Invesco Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Verition Fund Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →